Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 23, 2005Integrative Cancer TherapiesOpen Access

Coenzyme Q10 for Prevention of Anthracycline-Induced Cardiotoxicity

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does coenzyme Q10 prevent anthracycline-induced cardiotoxicity in patients undergoing cancer chemotherapy?

Population

Patients undergoing cancer chemotherapy that includes anthracyclines (such as doxorubicin and daunorubicin)

Design

Review

Authors

KCKenneth A. ConklinUniversity of California, Los Angeles

Discussion

Loading...

Member takes

Implication

Insufficient evidence for routine CoQ10 use; leaves open cardioprotective potential pending prospective RCTs in anthracycline regimens.

Structured PICO

Does coenzyme Q10 prevent anthracycline-induced cardiotoxicity in patients undergoing cancer chemotherapy?

P
Population
Patients undergoing cancer chemotherapy that includes anthracyclines (such as doxorubicin and daunorubicin)
I
Intervention
Coenzyme Q10 administered concurrently with chemotherapy
O
Outcome
Prevention of anthracycline-induced cardiotoxicity (cardiomyopathy)

Coenzyme Q10 may prevent anthracycline-induced cardiotoxicity by protecting cardiac mitochondria, potentially allowing for higher, safer cumulative doses of chemotherapy.

Limitations

  • limited clinical investigation

Cite This Study

Kenneth A. Conklin (2005) studied this question.

synapsesocial.com/papers/6a82561dce17449fdfffb88ehttps://doi.org/10.1177/1534735405276191

Topics

Heart failureHFrEF treatmentCardiomyopathy
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress1997 · 1,877 citations